Dr. Travis Young is the Vice President of Biologics at Calibr, the drug discovery and development division of Scripps Research. Travis and the team have created a new type of immunotherapy called “switchable” chimeric antigen receptor (CAR) T-cell therapy, which is already delivering precise and powerful therapies to patients with the most difficult to treat cancers. Listen as we talk about reengineering an individual’s immune T cells, promising clinical trials in leukemia and lymphoma patients, and using similar approaches to treat autoimmune diseases.

Show notes:

Episode transcript: https://www.scripps.edu/_files/images/2022_images/podcast-images/Travis-Young-transcript.pdf

Travis and his colleagues discuss ongoing therapies being developed at Calibr during the Front Row lecture series
https://www.youtube.com/watch?v=WRzQniqUlHo&t=2625s

Preliminary results of switchable CAR-T cells in lymphoma patients
https://www.scripps.edu/news-and-events/press-room/2021/20211208-calibr-announces-clinical-data-car-t-cells.html

Tweet: @CARTCellTherapy

Explore the Scripps Research Magazine
https://magazine.scripps.edu/

Subscribe to receive our monthly e-newsletter
https://signup.e2ma.net/signup/1879047/1890109/

@scrippsresearch on Twitter

Ver todos los episodios